SAN MATEO, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal Reflux Disease (GERD), today announced that data from its Transoral Incisionless Fundoplication (TIF®) registry show that outcomes from the procedure observed at 6-months remained stable across a range of evaluation methodologies at 12-month follow-up. The one-year findings showed that 78 percent of patients experienced elimination of troublesome heartburn symptoms and 83 percent stopped experiencing regurgitation. Seventy-four percent of patients completely stopped medical therapy with proton pump inhibitor medications.
Help employers find you! Check out all the jobs and post your resume.
